• NRW Bank announced a EUR 7 million investment in SRTD Biotech’s EUR 31.5 million seed round on November 9, 2026.
• Merieux Equity Partner led the round, with Boehringer Ingelheim Venture Fund participating as a co-lead investor alongside the bank.
• Jülich-based SRTD Biotech develops RNA-based therapeutics designed to activate only in diseased cells.
• Proceeds will advance preclinical development of treatments for cancer, autoimmune diseases and fibrosis.
• Other investors include Lilly Ventures, High-Tech Gründerfonds and family office Anobis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRW Bank published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.